Morgan Stanley Bionomics Limited Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNOX
# of Institutions
13Shares Held
1.65MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY1.59MShares$414,1800.01% of portfolio
-
Lynx1 Capital Management LP San Juan, PR550KShares$142,9140.09% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct316KShares$82,1600.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA34.1KShares$8,8750.0% of portfolio
-
Rhumbline Advisers Boston, MA8.3KShares$2,1580.0% of portfolio
About BIONOMICS LIMITED
- Ticker BNOX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 7,518,620
- Market Cap $1.95M
- Description
- Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has ...